AmerisourceBergen Corporation (ABC) Bundle
Understanding AmerisourceBergen Corporation (ABC) Revenue Streams
Understanding AmerisourceBergen Corporation’s Revenue Streams
AmerisourceBergen Corporation's revenue for the fiscal year 2024 was $294.0 billion, reflecting a 12.1% increase from the previous fiscal year’s revenue of $262.2 billion.
Breakdown of Primary Revenue Sources
The company's revenue is primarily derived from two segments:
- U.S. Healthcare Solutions: Revenue of $265.3 billion, an increase of 13.0% from $234.8 billion in the prior year.
- International Healthcare Solutions: Revenue of $28.6 billion, up 4.4% from $27.4 billion.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the fourth quarter of fiscal 2024 was 14.7%, with revenue reaching $79.1 billion, compared to $68.9 billion in the same quarter of the prior year.
Contribution of Different Business Segments to Overall Revenue
| Segment | Revenue FY 2024 | Revenue FY 2023 | Percentage Change |
|---|---|---|---|
| U.S. Healthcare Solutions | $265.3 billion | $234.8 billion | 13.0% |
| International Healthcare Solutions | $28.6 billion | $27.4 billion | 4.4% |
| Total Revenue | $294.0 billion | $262.2 billion | 12.1% |
Analysis of Significant Changes in Revenue Streams
In the fourth quarter of fiscal 2024, the U.S. Healthcare Solutions segment generated $71.7 billion, a 15.7% increase compared to $61.9 billion in the fourth quarter of fiscal 2023. Meanwhile, the International Healthcare Solutions segment reported revenue of $7.4 billion, which is a 5.5% increase from $7.0 billion in the same quarter of the previous fiscal year.
Overall, the increase in revenue is attributed to market growth driven by unit volume growth, particularly in products related to diabetes and specialty products sold to healthcare providers.
A Deep Dive into AmerisourceBergen Corporation (ABC) Profitability
A Deep Dive into Profitability Metrics
Gross Profit: In the fourth quarter of fiscal 2024, the gross profit was $2.5 billion, representing a 10.6% increase compared to the same period the previous year. The gross profit margin as a percentage of revenue was 3.15%, a decline of 12 basis points from the prior year quarter.
Operating Profit: The operating income for the fourth quarter of fiscal 2024 was $126.6 million, which indicates a significant 73.4% decrease year-over-year. The operating income margin was 0.16%, down from 0.69% in the previous year.
Net Profit: The net income attributable to the company was $3 million for the fourth quarter of fiscal 2024, a drastic decrease of 97.9% compared to $348.98 million in the same quarter the previous year.
Trends in Profitability Over Time
The fiscal year 2024 saw a revenue increase of 12.1% to $294 billion from $262 billion in fiscal year 2023. However, operating income declined by 7.1% to $2.18 billion from $2.34 billion.
Comparison of Profitability Ratios with Industry Averages
The adjusted gross profit margin for fiscal year 2024 was 3.31%, while the adjusted operating income margin stood at 1.24%. Comparatively, industry averages for similar companies typically range from 4% to 6% for gross profit margins and 2% to 4% for operating margins.
Analysis of Operational Efficiency
Operating Expenses: Total operating expenses in fiscal 2024 were $7.73 billion, representing an increase of 16.9% from the previous year's $6.62 billion. This increase was largely driven by a $418 million goodwill impairment charge.
Cost Management: The adjusted operating expenses as a percentage of revenue were 2.07% in fiscal 2024, a slight improvement from 2.18% in fiscal 2023.
| Metric | Q4 2024 | Q4 2023 | Change (%) |
|---|---|---|---|
| Gross Profit | $2.5 billion | $2.26 billion | +10.6% |
| Operating Income | $126.6 million | $476.9 million | -73.4% |
| Net Income | $3 million | $348.98 million | -97.9% |
| Adjusted Gross Profit Margin | 3.31% | 3.44% | -0.13% |
| Adjusted Operating Income Margin | 1.24% | 1.25% | -0.01% |
Debt vs. Equity: How AmerisourceBergen Corporation (ABC) Finances Its Growth
Debt vs. Equity: How AmerisourceBergen Corporation Finances Its Growth
As of the end of fiscal year 2024, AmerisourceBergen Corporation reported total short-term debt of $576.3 million and long-term debt of $3.8 billion. This signifies a significant reliance on debt financing to support its operations and growth initiatives.
The company’s debt-to-equity ratio stands at approximately 4.83, which is considerably higher than the industry average of around 1.0. This indicates that the company is leveraging debt significantly more than its equity, a strategy that can enhance returns but also increases financial risk.
In the recent fiscal year, AmerisourceBergen issued new debt instruments totaling $1.49 billion for acquisitions and operational funding. The company’s credit ratings from major agencies are currently Baa2 from Moody’s and BBB from S&P, reflecting a stable outlook despite the high debt levels. The company has also engaged in refinancing activities that have reduced its interest expense, which was reported at $157 million for the fiscal year.
AmerisourceBergen balances its capital structure by utilizing a mix of debt and equity financing. The company has consistently repurchased shares, reducing diluted shares outstanding to 200.3 million. This strategy of share repurchase indicates a commitment to returning value to shareholders while managing its equity base effectively.
| Debt Type | Amount (in millions) |
|---|---|
| Short-term Debt | $576.3 |
| Long-term Debt | $3,811.7 |
| Total Debt | $4,388.0 |
| Debt-to-Equity Ratio | 4.83 |
| Credit Rating (Moody's) | Baa2 |
| Credit Rating (S&P) | BBB |
| Interest Expense | $157.0 |
| Diluted Shares Outstanding | 200.3 million |
Through this strategic financial management, AmerisourceBergen Corporation continues to support its growth while navigating the complexities associated with high leverage.
Assessing AmerisourceBergen Corporation (ABC) Liquidity
Assessing Liquidity and Solvency
The liquidity and solvency of a company are critical indicators of its financial health. In this section, we will analyze the liquidity position, working capital trends, cash flow statements, and any potential liquidity concerns or strengths for the company.
Current and Quick Ratios
As of September 30, 2024, the company reported the following liquidity ratios:
- Current Ratio: 0.93
- Quick Ratio: 0.57
The current ratio indicates that the company has $0.93 in current assets for every $1.00 of current liabilities, while the quick ratio, which excludes inventory from current assets, shows a more stringent liquidity position of $0.57 .
Analysis of Working Capital Trends
Working capital, calculated as current assets minus current liabilities, is a crucial measure of short-term financial health. The company reported the following working capital figures:
| Fiscal Year | Current Assets ($ million) | Current Liabilities ($ million) | Working Capital ($ million) |
|---|---|---|---|
| 2024 | 47,718 | 50,942 | (3,224) |
| 2023 | 42,799 | 45,836 | (3,037) |
This table illustrates that working capital has slightly worsened from $(3,037) million in 2023 to $(3,224) million in 2024 .
Cash Flow Statements Overview
The cash flow statements provide insights into the company's operating, investing, and financing cash flow trends:
| Cash Flow Type | Fiscal Year 2024 ($ million) | Fiscal Year 2023 ($ million) |
|---|---|---|
| Operating Cash Flow | 2,453 | 2,580 |
| Investing Cash Flow | (618) | (2,602) |
| Financing Cash Flow | (2,331) | (2,222) |
The operating cash flow has decreased from $2,580 million in 2023 to $2,453 million in 2024. However, the investing cash flow reflects a significant improvement as it has reduced from $(2,602) million in 2023 to $(618) million in 2024 .
Potential Liquidity Concerns or Strengths
Despite the current ratio being below 1, indicating potential liquidity concerns, the company has managed to maintain positive cash flows from operations. The substantial reduction in cash used for investing activities suggests a focus on improving liquidity. However, the negative working capital trend and low quick ratio highlight areas of concern that may require attention .
Is AmerisourceBergen Corporation (ABC) Overvalued or Undervalued?
Valuation Analysis
To assess the valuation of the company, key metrics such as the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) are evaluated.
Price-to-Earnings (P/E) Ratio
The P/E ratio for the company is currently 18.2. This indicates a premium valuation compared to the industry average P/E of 15.5.
Price-to-Book (P/B) Ratio
The P/B ratio stands at 3.1, while the industry average is 2.4. This suggests that the stock may be overvalued based on book value.
Enterprise Value-to-EBITDA (EV/EBITDA)
The EV/EBITDA ratio is reported at 12.5, which is above the industry average of 10.7. This may indicate an overvaluation relative to earnings before interest, taxes, depreciation, and amortization.
Stock Price Trends
Over the last 12 months, the stock has experienced a price increase of 20%. The stock price was approximately $130 a year ago and is currently around $156.
Dividend Yield and Payout Ratios
The current dividend yield is 1.4%, with a payout ratio of 40%. This indicates a stable dividend policy while retaining a significant portion of earnings for growth.
Analyst Consensus
Analysts currently have a consensus rating of Hold on the stock, with 45% recommending it as a buy, 40% as a hold, and 15% as a sell.
| Metric | Company Value | Industry Average |
|---|---|---|
| P/E Ratio | 18.2 | 15.5 |
| P/B Ratio | 3.1 | 2.4 |
| EV/EBITDA | 12.5 | 10.7 |
| Stock Price (12 months ago) | $130 | |
| Current Stock Price | $156 | |
| Stock Price Increase | 20% | |
| Dividend Yield | 1.4% | |
| Payout Ratio | 40% | |
| Analyst Consensus | Hold |
Key Risks Facing AmerisourceBergen Corporation (ABC)
Key Risks Facing AmerisourceBergen Corporation
AmerisourceBergen Corporation faces a variety of internal and external risks that can impact its financial health significantly. These risks stem from industry competition, regulatory changes, and market conditions.
Industry Competition
The healthcare distribution industry is highly competitive. Key competitors include McKesson Corporation and Cardinal Health. As of fiscal year 2024, AmerisourceBergen's revenue reached $294.0 billion, a 12.1% increase year-over-year, but maintaining market share in a competitive landscape remains a challenge.
Regulatory Changes
Changes in healthcare regulations can impose additional costs or operational changes. The effective tax rate for the fourth quarter of fiscal 2024 was notably high at 94.0%, primarily due to a $418 million goodwill impairment charge related to PharmaLex. Such regulatory pressures can significantly affect profitability.
Market Conditions
Market fluctuations and economic downturns can impact demand for pharmaceuticals. The company's operating income for fiscal year 2024 was $2.2 billion, down 7.1% from the prior year, reflecting the impact of external market conditions.
Operational Risks
Operational risks include supply chain disruptions and increased operational costs. In the fourth quarter of fiscal 2024, operating expenses rose to $2.4 billion, a 33.2% increase from the previous year. This increase is attributed to various factors, including higher distribution and administrative costs.
Financial Risks
Financial risks involve interest rate fluctuations and credit risks. The net interest expense for the fourth quarter of fiscal 2024 was $21 million, a decrease of 65.6% compared to the previous year. However, significant fluctuations in interest rates can still pose a risk to future profitability.
Strategic Risks
Strategic risks include the potential for unsuccessful mergers and acquisitions. The company recently announced an acquisition of Retina Consultants of America, which could present integration challenges. Past acquisitions have included a $1.4 billion investment in PharmaLex, which also highlights the financial commitment and associated risks of such strategies.
Mitigation Strategies
To mitigate these risks, AmerisourceBergen has implemented various strategies, including diversifying its product offerings and enhancing operational efficiencies. The company has reported adjusted operating income growth expectations of 5% to 6.5% for fiscal year 2025. This conservative approach aims to balance growth while managing the inherent risks in the healthcare distribution sector.
| Risk Type | Description | Fiscal Year 2024 Impact | Mitigation Strategy |
|---|---|---|---|
| Industry Competition | Competition from major players in the healthcare distribution market. | Revenue increased by 12.1% to $294.0 billion. | Diversification of product offerings. |
| Regulatory Changes | Changes in healthcare regulations increasing operational costs. | Effective tax rate at 94.0% due to goodwill impairment. | Continuous compliance monitoring. |
| Market Conditions | Economic downturns affect demand for pharmaceuticals. | Operating income decreased by 7.1% to $2.2 billion. | Market analysis and adaptive strategies. |
| Operational Risks | Supply chain disruptions leading to increased costs. | Operating expenses rose to $2.4 billion, up 33.2%. | Enhancing supply chain resilience. |
| Financial Risks | Interest rate fluctuations impacting profitability. | Net interest expense of $21 million. | Hedging against interest rate risks. |
| Strategic Risks | Challenges in mergers and acquisitions. | Recent acquisition of Retina Consultants of America. | Thorough due diligence before acquisitions. |
Future Growth Prospects for AmerisourceBergen Corporation (ABC)
Growth Opportunities
Future growth prospects for the company are driven by several key factors:
Analysis of Key Growth Drivers
- Product Innovations: The company has seen significant revenue growth attributed to increased sales of specialty products, particularly those targeting diabetes and weight loss. In fiscal year 2024, U.S. Healthcare Solutions revenue reached $265.3 billion, a 13.0% increase from the previous year.
- Market Expansions: The International Healthcare Solutions segment also contributed to growth, with revenues of $28.6 billion, a 4.4% increase from fiscal 2023.
- Acquisitions: The recent acquisition of Retina Consultants of America is expected to enhance service offerings and expand market reach.
Future Revenue Growth Projections and Earnings Estimates
Projected revenue growth for fiscal year 2025 is anticipated to be between 5% to 6.5% for adjusted operating income, and 8% to 10% for adjusted diluted earnings per share (EPS). In fiscal year 2024, adjusted diluted EPS was $13.76, up from $11.99 in fiscal year 2023, reflecting an 8.1% increase in adjusted gross profit to $9.7 billion.
Strategic Initiatives or Partnerships
The company has implemented strategic initiatives such as:
- Enhancing its logistics capabilities through partnerships and technology investments.
- Expanding its global presence in specialty pharmaceuticals.
Competitive Advantages
The company maintains competitive advantages that position it for growth, including:
- A robust distribution network that supports efficient supply chain operations.
- Strong relationships with healthcare providers and pharmaceutical manufacturers.
Financial Performance Overview
| Metric | Fiscal Year 2024 | Fiscal Year 2023 | % Change |
|---|---|---|---|
| Revenue | $294.0 billion | $262.2 billion | 12.1% |
| Gross Profit | $9.9 billion | $8.96 billion | 10.6% |
| Operating Income | $2.18 billion | $2.34 billion | (7.1%) |
| Net Income | $1.51 billion | $1.73 billion | (12.3%) |
| Diluted EPS | $7.53 | $8.53 | (11.7%) |
In summary, the company is well-positioned to leverage its growth opportunities through strategic initiatives, product innovations, and market expansions while maintaining a strong financial outlook.
AmerisourceBergen Corporation (ABC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- AmerisourceBergen Corporation (ABC) Financial Statements – Access the full quarterly financial statements for Q4 2024 to get an in-depth view of AmerisourceBergen Corporation (ABC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View AmerisourceBergen Corporation (ABC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.